First Time Loading...

EyePoint Pharmaceuticals Inc
NASDAQ:EYPT

Watchlist Manager
EyePoint Pharmaceuticals Inc Logo
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Watchlist
Price: 20.67 USD -0.67%
Updated: Mar 29, 2024

Intrinsic Value

EYPT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one EYPT stock under the Base Case scenario is 3.44 USD. Compared to the current market price of 20.67 USD, EyePoint Pharmaceuticals Inc is Overvalued by 83%.

Key Points:
EYPT Intrinsic Value
Base Case
3.44 USD
Overvaluation 83%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
EyePoint Pharmaceuticals Inc

Backtest EYPT Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EYPT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Rising Revenues and Positive Clinical Trials
2023-Q4 Earnings Call

Rising Revenues and Positive Clinical Trials

In the final quarter of 2023, the company witnessed a surge in total net revenue, achieving $14 million versus $10.5 million in the prior year's quarter. This growth primarily resulted from recognized deferred revenue from the licensing of the YUTIQ franchise. Meanwhile, operational expenses took a dive due to strategic exits from the commercial business. Even with a $14.1 million net loss, there's notable progress compared to the earlier $43.5 million loss. The company's cash reserve stands strong at $331.1 million, expected to sustain key Phase III clinical trials for wet AMD treatment, EYP-1901, through 2026. Positive clinical trial data is anticipated for their Phase II PAVIA trial in Q2 2024, with hopes high for EYP-1901’s potential to revolutionize wet AMD treatment.

Financials

Balance Sheet Decomposition
EyePoint Pharmaceuticals Inc

Current Assets 344.8m
Cash & Short-Term Investments 331.1m
Receivables 805k
Other Current Assets 12.9m
Non-Current Assets 10.4m
PP&E 10.2m
Other Non-Current Assets 150k
Current Liabilities 63.3m
Accounts Payable 30.5m
Accrued Liabilities 17.5m
Other Current Liabilities 15.2m
Non-Current Liabilities 25.6m
Other Non-Current Liabilities 25.6m
Efficiency

Earnings Waterfall
EyePoint Pharmaceuticals Inc

Revenue
46m USD
Cost of Revenue
-4.6m USD
Gross Profit
41.4m USD
Operating Expenses
-116.5m USD
Operating Income
-75.1m USD
Other Expenses
4.3m USD
Net Income
-70.8m USD

Free Cash Flow Analysis
EyePoint Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

EYPT Profitability Score
Profitability Due Diligence

EyePoint Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
23/100
Profitability
Score

EyePoint Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

EYPT Solvency Score
Solvency Due Diligence

EyePoint Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
High Altman Z-Score
64/100
Solvency
Score

EyePoint Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EYPT Price Targets Summary
EyePoint Pharmaceuticals Inc

Wall Street analysts forecast EYPT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EYPT is 44.54 USD with a low forecast of 22.22 USD and a high forecast of 71.4 USD.

Lowest
Price Target
22.22 USD
7% Upside
Average
Price Target
44.54 USD
115% Upside
Highest
Price Target
71.4 USD
245% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EYPT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EYPT Price
EyePoint Pharmaceuticals Inc

1M 1M
-24%
6M 6M
+159%
1Y 1Y
+508%
3Y 3Y
+122%
5Y 5Y
+15%
10Y 10Y
-50%
Annual Price Range
20.67
52w Low
2.94
52w High
29.71
Price Metrics
Average Annual Return -22.41%
Standard Deviation of Annual Returns 45.27%
Max Drawdown -91%
Shares Statistics
Market Capitalization 1B USD
Shares Outstanding 49 830 800
Percentage of Shares Shorted 16.01%

EYPT Return Decomposition
Main factors of price return

What is price return decomposition?

EYPT News

Last Important Events
EyePoint Pharmaceuticals Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
EyePoint Pharmaceuticals Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

EyePoint Pharmaceuticals Inc Logo
EyePoint Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1B USD

Dividend Yield

0%

Description

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 122 full-time employees. The company went IPO on 2005-01-27. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The firm has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The firm is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.

Contact

MASSACHUSETTS
Watertown
480 Pleasant St Ste B300
+16179265000.0
https://eyepointpharma.com/

IPO

2005-01-27

Employees

122

Officers

President, CEO & Director
Dr. Jay S. Duker M.D.
Chief Business Officer
Mr. Michael Pine
Executive VP & CFO
Mr. George O. Elston
Senior Vice President of Manufacturing & Operations
Mr. Michael J. Maciocio
Senior VP & CTO
Mr. Said Saim Ph.D.
Chief Legal Officer & Company Secretary
Mr. Ron I. Honig Esq.
Show More
Chief People Officer & Senior VP of IT
Ms. Jennifer Leonard
Senior VP & Chief Medical Officer
Dr. Dario A. Paggiarino
Senior VP & Chief Commercial Officer
Mr. David Scott Jones
Chief Regulatory Officer
Ms. Isabelle Lefebvre
Show Less

See Also

Discover More
What is the Intrinsic Value of one EYPT stock?

The intrinsic value of one EYPT stock under the Base Case scenario is 3.44 USD.

Is EYPT stock undervalued or overvalued?

Compared to the current market price of 20.67 USD, EyePoint Pharmaceuticals Inc is Overvalued by 83%.